Key Advances in Multiple Myeloma Therapy: BCMA x CD3 Bispecific T-Cell Engagers / Antibodies Trials from #ASH2021

1) Welcome to the next installment of our key #oncology meeting highlights via #accredited #tweetorials from @onc_ce, your new (& only) home for the latest education from #experts on #cancer care. #Physicians #nurses #pharmacists #PAs and #NPs all earn 0.5h CE/#CME by following! 2) We now continue highlighting key data on #multiplemyeloma from @ASH_hematology 2021 … Continue reading Key Advances in Multiple Myeloma Therapy: BCMA x CD3 Bispecific T-Cell Engagers / Antibodies Trials from #ASH2021